Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) announced three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) in London, U.K., from November 12-15, 2024. The presentations will showcase data from the company's nomlabofusp Phase 1 studies and Phase 2 dose exploration study for Friedreich's ataxia treatment.
Nomlabofusp is a novel protein replacement therapy designed to deliver frataxin to mitochondria, addressing the root cause of Friedreich's ataxia. The presentations will cover:
- Effects of nomlabofusp on tissue frataxin levels, plasma lipid profiles, and gene expression
- Disease characteristics and tissue frataxin concentrations in adult patients
- Prediction of tissue frataxin levels with long-term nomlabofusp administration
Dr. Russell Clayton, Chief Medical Officer of Larimar, will give an oral presentation on November 14, 2024.
Positive
- Larimar Therapeutics is presenting data from multiple clinical studies at a major international conference
- The company's novel protein replacement therapy, nomlabofusp, targets the root cause of Friedreich's ataxia
- Presentations cover various aspects of nomlabofusp's effects and potential long-term benefits
Negative
- None.
News Market Reaction
On the day this news was published, LRMR gained 4.23%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at the annual International Congress for Ataxia Research (ICAR) being held November 12-15, 2024 in London, U.K. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich’s ataxia by delivering frataxin to mitochondria.
Larimar will present three posters during the conference, one of which will also be presented as an oral presentation. The poster presentations are as follows:
- Effect of nomlabofusp administration on tissue frataxin levels, plasma lipid profiles, and gene expression in patients with Friedreich’s ataxia
- Oral presentation by Dr. Russell Clayton, Chief Medical Officer of Larimar Therapeutics on Thursday November 14, 2024, at 5:07 PM CT
- Disease characteristics and tissue frataxin concentrations in adults with Friedreich’s ataxia participating in nomlabofusp interventional studies
- Prediction of tissue frataxin levels with long term administration of nomlabofusp in adults with Friedreich’s ataxia using modeling and simulations
About Nomlabofusp (CTI-1601)
Nomlabofusp is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein. Nomlabofusp has been granted Rare Pediatric Disease designation, Fast Track designation and Orphan Drug designation by the U.S. Food and Drug Administration (FDA), Orphan Drug Designation by the European Commission, and a PRIME designation by the European Medicines Agency. The FDA recently selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp (CTI-1601), is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
What is Larimar Therapeutics presenting at the International Congress for Ataxia Research (ICAR) 2024?
When and where is the International Congress for Ataxia Research (ICAR) 2024 taking place?
What is nomlabofusp and how does it work for Friedreich's ataxia?
Who will be giving the oral presentation for Larimar Therapeutics (LRMR) at ICAR 2024?
